Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 8
Submit an article Journal homepage
28
Views
4
CrossRef citations to date
0
Altmetric
Review

Advances in leishmaniasis chemotherapy and new relevant patents

Jose E Piñero Departamento de Parasitologia, Facultad de Farmacia, Universidad de La Laguna, Avda Astrofisico F Sanchez s/n, La Laguna, 38206 Tenerife, Canary Islands, Spain
,
Ignacio A Jiménez Departamento de Parasitologia, Facultad de Farmacia, Universidad de La Laguna, Avda Astrofisico F Sanchez s/n, La Laguna, 38206 Tenerife, Canary Islands, Spain
,
Basilio Valladares Instituto Universitario de Bio-Organica Antonio Gonzalez, Universidad de La Laguna, Avda. Astrofisico F Sanchez 2, La Laguna, 38206 Tenerife, Canary Islands, Spain. Instituto Canario de Investigacion del Cancer (ICIC)
&
Ángel G Ravelo Instituto Universitario de Bio-Organica Antonio Gonzalez, Universidad de La Laguna, Avda. Astrofisico F Sanchez 2, La Laguna, 38206 Tenerife, Canary Islands, Spain. Instituto Canario de Investigacion del Cancer (ICIC)
Pages 1113-1123 | Published online: 25 Feb 2005

Bibliography

  • DESJEUX P: Leishmaniasis: public healthaspects and control. Clin. Dermatol (1996) 14:417–423.
  • SHAW JJ: Taxonomy of the genus Leishmania: present and future trends and their implications. Mem. Inst. Oswaldo Cruz (1994) 89:471–478.
  • ASHFORD RW: The leishmaniases as model zoonoses. Ann. Trop. Med. Parasitol (1997) 91:693–701.
  • BORST P, OUELLETTE M: New mechanisms of drug resistance in parasitic protozoa. Ann. Rev. Microbial. (1995) 49:427–460.
  • GALLAGHER RB, MARX J, HINES PJ:Progress in parasitology. Science (1994) 264:1827.
  • HIRST SI, STAPLEY LA: Parasitology: thedawn of a new millennium. Parasitol . Today (2000) 16:1–3.
  • WORLD HEALTH ORGANIZATION: Annex 3: Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. In: The World Health Report. WHO, Geneva (2002):192–197.
  • SEAMAN J, MERCER AJ, SONDORP E: The epidemic of visceral leishmaniasis in western Upper Nile southern Sudan: course and impact from 1984 to 1994. Int. J. Epidemiol (1996) 25:862–871.
  • HEWITT S, REYBURN H, ASHFORD R, ROWLAND M: Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartment blocks. Trans. Roy Soc. Trop. Med. Hyg. (1998) 92:273–274.
  • GUERIN PJ, OLLIARO P, SUNDAR S et al: Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. (2002) 2:494–501.
  • DAVIES CR, KAYE P, CROFT SL, SUNDAR S: Leishmaniasis: new approaches to disease control. BE Med. j (2003) 326:377–382.
  • WORLD HEALTH ORGANIZATION: WHO Mode] prescribing information: drugs used IP parasitic diseases (2nd ed). WHO, Geneva (1995).
  • BERMAN JD: Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. (1997) 24:684–703.
  • HERWALDT BL, BERMAN JD: Recommendations for treating leishmaniasis with sodium stibogluconate Wentostan0 and review of pertinent clinical studies. Am. Trop . Med. Hyg. (1992) 46:296–306.
  • MOORE E, O'FLAHERTY D, HEUVELMANS H et al: Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya Bull. World Health Organ. (2001) 79:388–393.
  • ROBERTS WL, MCMURRAY WJ, RAINEY PM: Characterization of the antimonial antileishmanial agent meglumine antimonate (Glucantime). Antimicrob. Agents Chemother. (1998) 42:1076–1082.
  • PATHAK MK, YI T: Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. Immunol (2001) 167:3391–3397.
  • THAKUR CP, SINGH RK, HASSAN SM, KUMAR R, NARAIN S, KUMAR A: Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans. R. Soc. Trop. Med. Hyg. (1999) 93:319–323.
  • CROFT SL, URBINA JA, BRUN R: Chemotherapy of human leishmaniasis and trypanosomiasis. In: Trypanasomiesis and Leishmaniasis. Hide G, Mottram JC, Commbs GB, Holmes PH (Eds), CAB International, London, UK (1997):245–257.
  • BERMAN JD: Editorial Response: US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Infect . Dis. (1999) 28:49–51.
  • MURRAY HW: Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. (2001) 45:2185–2197.
  • BERMAN JD, BADARO R, THAKUR CP et al.: Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. (1998) 76:25–32.
  • MEYERHOFF A: US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. (1999) 28:49–51.
  • YARDLEY V, CROFT SL: A comparison ofthe activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. bit. J. Antimicrob. Agents. (2000) 13:243–248.
  • PINERO JE, MARTINEZ S, DEL CASTILLO A, PORTUS M, VALLADARES B: In vitro susceptibility of Leishmania infant strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone. Antimicrob. Chemother. (2002) 50:304–306.
  • SUNDAR S, MEHTA H, SURESH AV, SINGH SP, RAI M, MURRAY HW: Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin. Infect. Dis. (2004) 38:377–383.
  • MURRAY HW, BROOKS EB, DEVECCHIO JL, HEINZEL FP: Immuno enhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob. Agents Chemother. (2003) 47:2513–2517.
  • CROFT SL, NEAL RA, PENDERGAST W, CHAN JH: The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani Biochem Pharmacol (1987) 36:2633–2636.
  • KUHLENCORD A, MANIERA T, EIBL H, UNGER C: Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. (1992) 36:1630–1634.
  • LE FICHOUX Y, ROUSSEAU D, FERRUA B et al.: Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infant infection in BALM mice. Antimicrob. Agents Chemother. (1998) 42:654–658.
  • CROFT SL, SNOWDON D, YARDLEY V: The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosome cruzi and Trypanosome brucei Antimicrob. Chemother. (1996) 38:1041–1047.
  • CROFT SL, SEIFERT K, DUCHENE M: Antiprotozoal activities of phospholipid analogues. MoL Biochem. Parasitol (2003) 126:165–172.
  • LUX H, HART DT, PARKER PJ, KLENNER T: Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv. Exp. Med. Biol. (1996) 416:201–211.
  • LUX H, HEISE N, KLENNER T, HART D, OPPERDOES FR: Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol (2000) 111:1–14.
  • PARIS C, LOISEAU PM, BORIES C, BREARD J: Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. (2004) 48:852–859.
  • SUNDAR S, ROSENKAIMER F, MAKHARIA MK et al: Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 352:1821–1823.
  • SUNDAR S, JHA TK, THAKUR CP et al:Oral miltefosine for Indian visceral leishmaniasis. N Engl. J. Med. (2002) 347:1739–1746.
  • PRASAD R, KUMAR R, JAISWAL BP, SINGH UK: Miltefosine: an oral drug for visceral leishmaniasis. Indianj Pediatr. (2004) 71:143–144.
  • BHATTACHARYA SK, JHA TK, SUNDAR S et al: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. (2004) 38:217–221.
  • SOTO J, TOLEDO J, GUTIERREZ P et al.: Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. (2001) 33:57–61.
  • SOTO J, ARANA BA, TOLEDO J et al:Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266–1272.
  • ESCOBAR P, MATU S, MARQUES C, CROFT SL: Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET- 18- OCH3 (edelfosine) and amphotericin B. Acta Trop. (2002) 81:151–157.
  • PEREZ-VICTORIA JM, PEREZ-VICTORIA FJ, PARODI-TALICE A et al.: Alkyl-lysophospholipid resistance in multidrug resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. (2001) 45:2468–2474.
  • SHERWOOD JA, GACHIHI GS, MUIGAI RK et al: Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Infect. Dis. (1994) 19:1034–1039.
  • DIETZE R, CARVALHO SF, VALLI LC et al: Phase II trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi Am. I Trop. Med. Hyg. (2001) 65:685–689.
  • MBUI J, RASHID R, LODENYO H et al.:Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report. East Afr. Med. J. (2003) 80:440–442.
  • THAKUR CP, KANYOK TP, PANDEY AK, SINHA GP, MESSICK C, OLLIARO P: Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized Phase-II clinical study. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:432–433.
  • KAGER PA, REES PH, WELLDE BT, HOCKMEYER WT, LYVERLY WH: Allopurinol in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1981) 75:556–559.
  • CHUNGE CN, GACHIHI G, MUIGAI R: Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans. R. Soc. Trop. Med. Hyg. (1985) 79:715–718.
  • JHA TK. Evaluation of allopurinol in thetreatment of kala-azar occurring in North Bihar, India. Trans. R. Soc. Trop. Med. Hyg. (1983) 77:204–207.
  • RAGUSA R, DI CATALDO A, SAMPERI P, SCHILIRO G: Treatment of visceral leishmaniasis with meglumine and allopurinol. Am. J. Dis. Child (1993) 147:611–612.
  • DAS VN, RANJAN A, SINHA AN et al: A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. .1. Assoc Physicians India (2001) 49:609–613.
  • RODRIGUEZ N, BAILEY BN, MARTIN MB, OLDFIEL E, URBINA JA, DOCAMPO R: Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate../. Infect. Dis. (2002) 186:138–140.
  • DOCAMPO R, MORENO SN: Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites. Curt: Drug Targets Infect. Disord. (2001) 1:51–61.
  • AKENDENGUE B, NGOU-MILAMA E, LAURENS A, HOCQUEMILLER R: Recent advances in the fight against leishmaniasis with natural products. Parasite (1999) 6:3–8.
  • CHAN-BACAB MJ, PENA -RODRIGUEZ LM: Plant natural products with leishmanicidal activity. Nat. Prod. Rep. (2001) 18:674–688.
  • FOURNET A, MUNOZ V: Natural products as trypanocidal, antileishmanial and antimalarial drugs. Curt: Top. Med. Chem. (2002) 2:1215–1237.
  • NIELSEN SF, CHRISTENSEN SB, CRUCIANI G, KHARAZMI A, LILJEFORS T: Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. Med . Chem. (1998) 41:4819–4832.
  • KAYSER 0, KIDERLEN AF: In vitro leishmanicidal activity of naturally occurring chalcones. Phytother. Res. (2001) 15:148–152.
  • HERMOSO A, JIMENEZ IA, MAMANI ZA et al: Antileishmanial activities of dihydrochalcones from Piper elongatum and synthetic related compounds. Structural requirements for activity. Bioorg. Med. Chem. (2003) 11:3975–3980.
  • CHEN M, ZHAI L, CHRISTENSEN SB, THEANDER TG, KHARAZMI A: Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob. Agents Chemother. (2001) 45:2023–2029.
  • FOURNET A, FERREIRA ME, ROJAS DE ARIAS A et al: In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob. Agents Chemother. (1996) 40:2447–2451.
  • MEDDA S, MUKHOPADHYAY S, BASU MK: Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J. Antimicrob. Chemother. (1999) 44:791–794.
  • MAES L, VANDEN BERGHE D, GERMONPREZ N et al: In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansee against visceral leishmania species. Antimicrob. Agents Chemother. (2004) 48:130–136.
  • LUQUE-ORTEGA JR, MARTINEZ S, SAUGAR JM et al.: Fungus-elicited metabolites from plants as an enriched source for new leishmanicidal agents: antifungal phenyl-phenalenone phytoalexins from the banana plant (Musa acuminate) target mitochondria of Leishmania donovani promastigotes. Antimicrob. Agents Chemother. (2004) 48:1534–1540.
  • MURRAY HW, GRANGER AM, MOHANTY SK: Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma and interleukin-2-independent. I Infect. Dis. (1991) 163:622–624.
  • BADARO R, FALCOFF E, BADARO FS et al.: Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl. I Med. (1990) 322:16–21.
  • SUNDAR S, SINGH VP, SHARMA S, MAKHARIA MK, MURRAY HW: Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. Infect . Dis. (1997) 176:1117–1119.
  • HARRISON CJ, MILLER RL, BERNSTEIN DI: Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. (1994) 38:2059–2064.
  • TESTERMAN TL, GERSTER JF, IMBERTSON LM et al: Cytokine induction by the immunomodulators imiquimod and S-27609. I Leukoc. Biol. (1995) 58:365–372.
  • BUATES S, MATLASHEWSKI G: Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. (1999) 179:1485–1494.
  • AREVALO I, WARD B, MILLER R et al: Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. (2001) 33:1847–1851.
  • SELZER PM, CHEN X, CHAN VJ et al: Leishmania major molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp. Paresitol (1997) 87:212–221.
  • MOTTRAM JC, BROOKS DR, COOMBS GH: Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions. Curt: Opin. Microbiol (1998) 1:455–460.
  • MCKERROW JH: Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Intl Paresitol (1999) 29:833–837.
  • MCKERROW JH, ENGEL JC, CAFFREY CR: Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. (1999) 7:639–644.
  • SALVATI L, MATTU M, COLASANTI M et al: NO donors inhibit Leishmania infantum cysteine proteinase activity. Bloch/m. Biophys. Acta (2001) 1545:357–366.
  • ZEINA B, BANFIELD C, AL-ASSAD S: Topical glyceryl trinitrate: a possible treatment for cutaneous leishmaniasis. Clin. Exp. Dermatol (1997) 22:244–245.
  • LOPEZ-JARAMILLO P, RUANO C, RIVERA J et al.: Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet (1998) 351:1176–1177.
  • DAVIDSON RN, YARDLEY V, CROFT SL, KONECNY P, BENJAMIN N: A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:319–322.
  • BOCEDI A, GRADONI L, MENEGATTI E, ASCENZI P: Kinetics of parasite cysteine proteinase inactivation by NO-donors. Biochem. Biophy Res. Commun. (2004) 315:710–718.
  • JUNGHAE M, RAYNES JG: Activation ofp38 mitogen-activated protein kinase attenuates Leishmania donovani infection in macrophages. Infect. Immun. (2002) 70:5026–5035.
  • AWASTHI A, MATHUR R, KHAN A et al.: CD40 signalling is impaired in L . major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J. Exp. Med. (2003) 197:1037–1043.
  • YEATES C: Sitamaquine GlaxoSmithKline /Walter Reed Army Institute. Curr. Opin. Investig. Drugs (2002) 3(10):1446–1452.
  • SUNDAR S, RAI M: Advances in the treatment of leishmaniasis. Current Opinion in Infectious Diseases. (2002) 15 (6):593–598.
  • MARTY P, ROSENTHAL E: Treatment ofvisceral leishmaniasis: a review of current treatment practices. Expert Opin. Pharmacother. (2002) 3(8):1101–1108.
  • KAMINSKY R: Miltefosine Zentaris. Curr. Opin. Investig. Drugs (2002) 3(4):50–54.
  • CROFT SL, YARDLEY V: Chemotherapy of leishmaniasis. Curl: Pharm. Dec. (2002) 8:319–342.
  • CROFT SL, COOMBS GH: Leishmaniasis -current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol (2003) 19:502–508.

Websites

  • http://www.whainthdr/diseases/leish/default .htm Leishmaniasis Webpage of TDR.
  • http://www.whaint/health_topics/leishmania sis/en/ Leishmaniasis Webpage of WHO.
  • http://www.neglecteddiseases.org/1–2.pdf Drugs for the Treatment of Visceral Leishmaniasis: Current Status, Needs, and a Proposed R&D Agenda.
  • http://www.ebi.ac.uldparasites/leish.html Leishmania genome Network.
  • http:\\www.ebi.ac.uklparasites/leish.html The Leishmania Proteome Classification and Analysis.
  • http://www.zentaris.com/ Zentaris developed Impavido° (Miltefosine) in co-operation with the WHO to fight the deadly visceral leishmaniasis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.